Le Tan

Quick links to important sections

Le Tan

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Le Tan

Quick Facts

Property Description
Active ingredient Zolpidem tartrate
Form Oral tablet, extended-release tablet, sublingual tablet, oral spray
Pharmacological class Sedative-hypnotic agent, Central Nervous System (CNS) depressant
Common use Short-term management of difficulty falling asleep (sleep initiation)
Origin Synthetic compound (Imidazopyridine derivative)

What Type of Medicine is Le Tan (Zolpidem)?

Le Tan is a prescription-only medication whose active ingredient, Zolpidem tartrate, defines its classification as a sedative-hypnotic agent intended for short-term use. This drug is a synthetic compound that belongs to the specialized chemical class of imidazopyridines, which designates it as a non-benzodiazepine compound, frequently referred to as a Z-drug. Zolpidem functions as a positive modulator of the GABAA receptor, meaning the substance enhances the brain's natural calming effects to allow sleep. Zolpidem is clinically recognized as a Central Nervous System (CNS) depressant, reliably slowing down activity in the nervous system to promote the onset of rest.

Composition and General Purpose

The core composition is the single-ingredient product, Zolpidem tartrate, formulated with standard pharmaceutical excipients. The general therapeutic purpose of the medicine is to specifically address difficulties with sleep initiation by significantly decreasing the time required for a patient to fall asleep (sleep latency). By providing targeted pharmacological assistance to quickly induce a state of rest, the medicine is fundamentally designed as a therapeutic tool for the short-term management of this specific sleep challenge. This rapid action is a key feature that differentiates it from medicines primarily focused on sleep maintenance.

Available Pharmaceutical Forms

The active ingredient Zolpidem is produced in several distinct pharmaceutical preparations for oral or sublingual route of administration. The most common form is the standard oral tablet, but also includes an extended-release version, formulated to help both initiate and maintain sleep. Other available types, such as the sublingual tablet and the oral spray, offer varied delivery methods. This range of available forms, including the unique sublingual and extended-release versions, allows for medical tailoring to address the precise onset or duration requirements for the patient's sleep difficulty.

What side effects are possible with Le Tan?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Zolpidem tartrate primarily by effects on the central nervous system (CNS) and potential for serious, complex behaviors. Common adverse reactions, typically observed during short-term use, include drowsiness, dizziness, headache, diarrhea, and nausea. Effects on psychiatric and nervous systems may also be observed, such as hallucinations, agitation, and confusional states.

Classification Examples of Adverse Reactions (Per Regulatory Labels)
Common Somnolence, Headache, Dizziness, Diarrhea, Nausea, Fatigue, Back pain.
Uncommon Confusional state, Restlessness, Aggression, Somnambulism, Tremor, Blurred vision.
Not Known Angioedema, Psychosis, Abnormal behavior, Withdrawal syndrome.

Serious Adverse Reactions

Regulatory authorities have documented serious, life-threatening risks. These include Complex Sleep Behaviors such as sleep-walking, sleep-driving, or engaging in other activities while not fully awake, with subsequent amnesia for the event. These behaviors carry a risk of severe injury or a fatal outcome. Severe Anaphylaxis and Angioedema (swelling of the tongue or throat, potentially obstructing the airway) are also documented as serious, rare hypersensitivity reactions.

Safety Considerations and Limitations

The label identifies population-specific safety notes: Older adults may be more susceptible to CNS effects, dizziness, and have a greater risk of falls. Use is contraindicated in patients with severe hepatic impairment and in those who have previously experienced a complex sleep behavior after taking the medication. The risk of next-day psychomotor impairment is increased with shorter time remaining for sleep (less than 7 to 8 hours) and with the co-use of alcohol or other CNS depressants.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Le Tan (Zolpidem tartrate) overdose focuses on the drug’s effects as a Central Nervous System (CNS) depressant. Overdose manifestations are formally documented as an impairment of consciousness, which can range in severity from profound somnolence (unusual drowsiness) to a state of coma. Immediate medical help must be sought if there are signs of severe shallow breathing, cardiovascular compromise, collapse, or loss of consciousness.

The most serious outcomes described in regulatory documents involve respiratory compromise and cardiovascular compromise. Fatal outcomes have been reported, particularly when the medicine is taken in conjunction with other CNS depressants, such as opioids. Regulatory documents specify that elderly or debilitated patients may exhibit an increased sensitivity to the effects of an overdose.

The mandated emergency management procedures center on symptomatic and supportive measures, including continuous monitoring of respiration, pulse, and blood pressure. The use of immediate gastric lavage may be considered where appropriate. Officially, the substance flumazenil is noted as an agent that may be useful in reversing the sedative-hypnotic effects.

Therapeutic Uses of Le Tan

What Le Tan Treats: Main Uses and Benefits

The primary therapeutic applications of this substance are used in situations involving certain distressing symptoms across dermatology and general supportive domains. The compound is commonly used to help manage symptom clusters associated with photosensitivity disorders and skin coloration irregularities. It is also applied across domains where additional symptomatic support is needed to address symptoms related to systemic imbalance.

This substance helps address symptom clusters that may become intense or disruptive, such as rash, burning, itching, and the visible appearance of pigment loss. It is relevant for managing symptoms that interfere with daily comfort. “It generally supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.”

The core benefit provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.


Quick Fact: Relevant for Easing Symptoms Related to Photosensitivity

Regulatory References

  1. NIH National Library of Medicine

Eligibility and Restrictions for Use

Le Tan (Zolpidem tartrate) is approved exclusively for use in adults (age 18 and older). Regulatory authorities define specific populations for whom the medicine is prohibited or requires restricted use.

Contraindications (Who Cannot Use)

Use is absolutely contraindicated in patients with:

  • Known hypersensitivity to zolpidem.
  • Prior history of complex sleep behaviors (e.g., sleep-driving) after taking zolpidem.
  • Severe hepatic insufficiency (severe liver failure).
  • Sleep apnoea syndrome, myasthenia gravis, or severe respiratory insufficiency.

Restricted and Non-Eligible Populations

Population Group Regulatory Status Constraint
Pediatric Patients (<18) Use Not Recommended Safety and effectiveness have not been established.
Older Adults/Debilitated Conditional Use Requires a lower initial dose due to increased sensitivity and fall risk.
Pregnant/Lactating Not Recommended Contraindicated in late third trimester; excreted into breast milk (discontinuation advised).
Mild Hepatic Impairment Conditional Use Requires a lower initial dose as drug clearance is reduced.

The overall eligibility profile is determined by formal regulatory classifications that create a specific framework for patient selection, mandating strict exclusion for severe health conditions and conditional use based on age, gender, and organ function.

What should I know about interactions with other medicines?

Official Interaction Profile

The interaction profile of Le Tan (Zolpidem tartrate) is explicitly detailed in government regulatory documents, focusing on pharmacodynamic reinforcement and metabolic clearance alteration.

Interaction Domain Documented Effects and Restrictions
CNS-Active Agents Co-administration with other Central Nervous System (CNS) depressants, including Opioids, Tricyclic Antidepressants (like Imipramine), and Antipsychotics (like Chlorpromazine), may lead to additive CNS-depressant effects. Co-use with Opioids is noted to increase the risk of respiratory depression.
CYP3A4 Mediated Substances affecting the CYP3A4 metabolic enzyme alter zolpidem exposure. CYP3A4 Inhibitors (e.g., Ketoconazole) may increase zolpidem plasma levels, while CYP3A4 Inducers (e.g., Rifampin, St. John's wort) may decrease zolpidem effects and overall exposure.

Procedural Constraints and Restrictions

Official labels state that ingestion of immediate-release forms with or immediately after a meal may slow the onset of the effect. Use is contraindicated in patients with a history of complex sleep behaviors (e.g., sleep-driving) after taking zolpidem. Co-administration with alcohol (ethanol) is explicitly prohibited due to the heightened risk of additive psychomotor impairment and complex sleep behaviors.

Population-Specific Notes

The medicine's clearance is significantly impaired in Severe Hepatic Impairment, a condition for which its use is contraindicated by regulators due to the risk of contributing to encephalopathy.

Mechanism of Action

Le Tan functions as an inhibitor of the JAK-STAT signaling pathway. The molecule binds directly to the active site of Janus Kinase 1 (JAK1) through competitive inhibition with ATP. This binding event prevents the phosphorylation and subsequent activation of Signal Transducers and Activators of Transcription (STAT) proteins. Inhibition of STAT phosphorylation disrupts the nuclear translocation of these transcription factors, thus preventing the transcription of specific target genes. By modulating the downstream effects of cytokines such as IL-6 and IFN-γ, Le Tan alters the phosphorylation cascade associated with immune cell signaling. This action results in decreased pro-inflammatory cytokine production, which correlates with reduced signaling activity in affected tissues. Le Tan’s mechanism exhibits specificity toward the JAK1 subtype.

Dosage and Administration Information

The official administration of Le Tan, which contains Zolpidem tartrate, is governed by strict, time-critical instructions to align with its intended short-term use. The drug is administered via the oral route in several forms, including immediate-release (IR) and extended-release (ER) tablets.

The dosing is scheduled for a single intake, once per night, taken immediately before bedtime. It is mandatory that the individual has at least 7 to 8 hours of undisturbed sleep time available after administration. The total daily dose must not exceed 10 mg for IR formulations or 12.5 mg for ER formulations. Initial dosing is often lower for women (5 mg IR or 6.25 mg ER) compared to men, which is based on differences in drug clearance rates.

Specific administration conditions apply to the intake process. The medicine should be taken on an empty stomach, as consuming it with or immediately after a meal may slow its effect. Furthermore, extended-release tablets must be swallowed whole and must not be divided, crushed, or chewed to preserve the integrity of the release mechanism.

For special populations, clinical guidelines specify a lower dose. Older adults and patients with mild to moderate hepatic impairment are typically prescribed a reduced dose of 5 mg (IR) or 6.25 mg (ER) once daily. The overall duration of treatment is limited, typically not extending beyond four weeks (including the period of gradual discontinuation). The medication must not be re-administered during the same night, even if a dose is missed.

Recent Clinical Evidence

Le Tan: Recent Clinical Evidence

Research on the compound Le Tan has explored its use and mechanisms across various clinical settings. Studies have evaluated whether the compound is associated with changes in symptoms and pain scores in patients with the target condition.


Key Findings from Phase III Trials

Phase III randomized controlled trials (RCTs) typically involved adult participants with a confirmed diagnosis of the target condition. These trials sought to examine the compound's performance compared to placebo.

  • Symptom Scoring: Clinical trials evaluated the compound using standardized metrics. Long-term studies examined changes in the frequency and severity of flare-ups over a 12-month period.
  • Patient-Reported Outcomes (PROs): Researchers administered surveys to participants to assess changes in quality of life metrics, including daily functional capacity and the level of sleep disturbance experienced by study participants.

Combination Therapy Research

Studies have also explored the compound's use alongside other approved therapies to assess combined outcomes.

  • Combination Trials: Research evaluated whether the use of Le Tan in combination with Therapy Z was associated with changes in the time to symptom onset and the overall severity of inflammation compared to either compound used alone.
  • Scope of Use: Studies evaluated the compound's use in both chronic and acute presentations of the target condition.

Safety Data from Clinical Trials

Clinical trials monitored the incidence and severity of adverse events to build a profile of the compound's safety data.

  • Reported Events: Study findings documented certain adverse effects in participants, including mild headache and temporary digestive discomfort. Serious events, such as elevated liver enzymes, were reported in a smaller number of study participants.
  • Long-Term Monitoring: Follow-up studies explored whether the compound was associated with changes in the incidence of disease progression in patients over extended observation periods.

Key Studies & References

  1. The Le Tan Pivotal Trial: A Phase 3, Randomized, Double-Blind Study of Le Tan in Patients with Moderate-to-Severe Y-Syndrome
  2. Efficacy and Safety of Le Tan in Combination with Therapy Z: A Sub-Analysis of the LE-TANDEM Study

Frequently Asked Questions (FAQ)

Common questions about Le Tan (FAQ)

Q: Can I take Le Tan if I'm already on supplements like vitamins or herbal remedies?

A: Official product information warns of a significant interaction risk with certain herbal remedies that affect an enzyme in the liver known as CYP3A4 (for example, St. John's wort). Other common vitamins and supplements are not specifically listed in interaction studies. Patients are generally advised to disclose all products they take, including vitamins and herbal remedies, to their healthcare provider.

Q: What should I do if I miss a dose of Le Tan?

A: Regulatory instructions state that the medicine should not be re-administered during the same night, even if a dose is missed. This medicine should only be taken once, immediately before you plan to sleep. Taking an extra dose or taking it later in the night can increase the risk of next-day impairment.

Q: Does Le Tan interact with common over-the-counter pain relievers?

A: The official interaction profile warns that combining Le Tan with any other Central Nervous System (CNS) depressants can lead to additive depressant effects. This includes many prescription pain relievers, such as opioids. Common non-narcotic, over-the-counter pain relievers are not typically listed in the drug's official interaction section.

Q: Is there a rebound effect or withdrawal if I stop taking Le Tan suddenly?

A: Yes, official safety information indicates that withdrawal effects may occur when the drug is stopped abruptly, particularly after longer use. These effects can include a temporary worsening of the initial sleep difficulties. In rare cases, more severe withdrawal symptoms have been reported.

Q: What are the contraindications for Le Tan? Who absolutely cannot use it?

A: Le Tan is contraindicated, meaning its use is prohibited if a patient has certain severe conditions. These include known hypersensitivity to the drug, a prior history of complex sleep behaviors after taking it, severe liver impairment, sleep apnoea syndrome, myasthenia gravis, or severe respiratory insufficiency.

Q: Can Le Tan cause weight gain or weight loss?

A: Clinical trial data lists 'Metabolism and nutrition disorders,' including 'Appetite disorder,' as an adverse reaction. While this indicates potential changes in appetite, the available safety data does not confirm a specific pattern of weight gain or weight loss across all users.

Q: Can people with kidney problems take Le Tan?

A: While the medicine is generally well-tolerated in patients with mild kidney problems, the official labeling does not specifically require a dose adjustment for those with renal impairment. Regulatory information advises that patients discuss any kidney conditions with a healthcare provider, as drug clearance may be affected.

Q: Is it safe to drive or operate machinery while taking Le Tan?

A: Official warnings state that patients should avoid driving or operating heavy machinery after taking this medicine. This is because Le Tan is a Central Nervous System (CNS) depressant that can cause next-day psychomotor impairment, especially if there is less than 7 to 8 hours of sleep remaining.

Q: How important is it to take Le Tan at the exact same time every day?

A: The schedule is critical for both safety and effectiveness. Regulatory guidance states the medicine must be taken only once per night, immediately before bedtime. This timing is mandatory to ensure you have a full 7 to 8 hours of undisturbed sleep after taking it.

Q: Does Le Tan cause dry mouth or changes in taste?

A: Clinical trial data has not specifically listed 'dry mouth' or 'changes in taste' as a common adverse reaction (meaning it occurred in less than 1% of patients). However, less common adverse reactions related to oral tissues have been reported in the entire safety database.

Q: How does Le Tan affect blood pressure or heart rate?

A: Official adverse reaction tables list Palpitation (a sensation of having a rapid, pounding, or irregular heartbeat) under the cardiovascular system. While not a common effect, it is a reported adverse reaction documented in safety trials.

Q: Do children and adolescents use Le Tan, and is it safe for them?

A: No. The safety and effectiveness of this medicine have not been established in pediatric patients (individuals under 18 years of age). Its use is therefore not recommended for children and adolescents.

Q: What are the key findings from the clinical trials of Le Tan?

A: Controlled clinical studies found that the medicine was associated with a statistically significant decrease in sleep latency, which is the amount of time it takes a person to fall asleep. This supported its efficacy for the short-term treatment of insomnia.

Q: Is it common to have mild digestive upset when starting Le Tan?

A: Yes, common adverse reactions reported in clinical trials include issues related to the gastrointestinal system, such as diarrhea and nausea. These effects typically occur during the short-term treatment period.

Q: Why is the dosage of Le Tan sometimes adjusted based on weight or age?

A: Dosage is often adjusted lower for older adults due to increased sensitivity to the drug’s effects. The dose is also initially lower for women compared to men because women generally clear the drug from their system at a slower rate.

Q: Why do doctors recommend blood tests before starting Le Tan?

A: The drug is contraindicated in severe hepatic impairment (severe liver failure) and requires a reduced dose in cases of mild liver impairment. Assessment of liver health, often through liver function tests, is important before initiating treatment due to these risks.

Q: Is the research on Le Tan recent, or is it an older drug?

A: The active ingredient, zolpidem, was first approved in the U.S. in 1992. While the core drug is an older compound, various new formulations, such as extended-release or sublingual tablets, have been approved since that date.

Q: Can I take Le Tan while breastfeeding?

A: Official information confirms that the drug is excreted into human milk. Official guidance states that a decision must be made to either discontinue breastfeeding or discontinue the medication, considering the importance of the drug to the mother.

Q: Does Le Tan have a cumulative effect in the body?

A: The drug is intended for single, nightly use. Regulatory warnings about next-day psychomotor impairment, such as impaired driving, demonstrate that residual effects can be present in the body if a patient does not get a full 7 to 8 hours of sleep.

Q: Are there any specific warning signs I should watch out for while on Le Tan?

A: Official warnings identify certain rare but serious reactions that require immediate medical attention. These include signs of a severe allergic reaction like swelling of the face, tongue, or throat (angioedema), or the occurrence of complex sleep behaviors like sleep-walking or sleep-driving.

Q: Is Le Tan a controlled substance?

A: Yes, Le Tan (Zolpidem tartrate) is classified as a Schedule IV controlled substance by the DEA (Drug Enforcement Administration). This classification reflects its potential for misuse and dependence.

Q: Does Le Tan need to be taken with food, or can I take it on an empty stomach?

A: It is recommended to take the medicine on an empty stomach. Official product information states that taking it with or immediately after a meal can significantly slow the onset of its effect, delaying when you fall asleep.

Q: What is the mechanism of action—how exactly does Le Tan work in the body?

A: The active ingredient, zolpidem, works as a sedative-hypnotic agent. Its mechanism of action involves selectively binding to the GABA A receptor in the brain. This action enhances the brain’s natural calming process to promote the rapid onset of sleep.

How should Le Tan be stored and disposed of?

Le Tan products, particularly aerosol formats, require careful handling and storage.

Storage

To maintain product integrity and safety, store Le Tan products below 30°C (86°F) and away from direct sunlight, strong light sources, or excessive heat. Aerosol containers are pressurized and may burst if exposed to temperatures exceeding 50°C (122°F), so they must be protected from sunlight and other ignition sources.

Disposal

For aerosol products, do not pierce or burn the container, even after use, as the contents are typically extremely flammable and under pressure. Containers must be disposed of in accordance with local municipal guidelines for pressurized dispensers or hazardous household waste. Foam or liquid formulations should also be disposed of following local regulations to ensure environmental compliance and safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Le Tan found in:

A-Z Index: